TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 59nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 1.48nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 197nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 197nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.950nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.460nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent